SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Shilpa Medicare informs about disclosure

26 Aug 2024 Evaluate
Shilpa Medicare has informed that the company has successfully completed phase 3 clinical studies of its novel product SMLNUD07 - Nor Ursodeoxycholic Acid (NorUDCA) tablets that is expected to revolutionise the treatment of patients suffering from Nonalcoholic Fatty Liver Disease (NAFLD).

The above information is a part of company’s filings submitted to BSE.

Shilpa Medicare Share Price

414.50 2.95 (0.72%)
20-Apr-2026 14:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.40
Dr. Reddys Lab 1234.00
Cipla 1233.00
Zydus Lifesciences 939.55
Lupin 2330.45
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×